Medicare Enrolled
Dr. Clan Hahn, M.D.
Hematology & Oncology · Los Angeles, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hahn from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hahn?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hahn
Dr. Clan Hahn is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Hahn performed 6,093 Medicare services across 851 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hahn received a total of $8,039 from 46 pharmaceutical and/or device companies across 321 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hahn is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 32% volume in CA
$8,039 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,093
Medicare services
Top 32% in CA for hematology & oncology
851
Unique beneficiaries
$45
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~321 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,054 | $107 | $210 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,000 | $0 | $15 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
785 | $101 | $160 |
| Injection, granisetron hydrochloride, 100 mcg | 700 | $0 | $20 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
677 | $8 | $10 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
534 | $14 | $30 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
220 | $122 | $240 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
206 | $13 | $25 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
203 | $12 | $25 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
155 | $1 | $20 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
135 | $26 | $50 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
123 | $144 | $388 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
79 | $132 | $270 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
74 | $1 | $300 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
62 | $1 | $20 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
35 | $67 | $110 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
30 | $21 | $40 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
21 | $79 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.2% high complexity
43.3% medium
50.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,039
Total received (2018-2024)
Avg $1,608/year across 5 years
Top 35% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
321
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,039 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,216
2023
$2,336
2022
$628
2019
$20
2018
$839
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$404
Merck Sharp & Dohme LLC
$361
E.R. Squibb & Sons, L.L.C.
$335
PFIZER INC.
$316
Secura Bio, Inc.
$286
Adaptive Biotechnologies Corporation
$244
Bayer Healthcare Pharmaceuticals Inc.
$236
Gilead Sciences, Inc.
$190
Eisai Inc.
$175
Incyte Corporation
$169
Celgene Corporation
$156
Exelixis Inc.
$154
ARRAY BIOPHARMA INC
$110
Daiichi Sankyo Inc.
$106
Novartis Pharmaceuticals Corporation
$89
PharmaEssentia USA Corporation
$88
Mirati Therapeutics, Inc.
$86
AstraZeneca Pharmaceuticals LP
$78
EMD Serono, Inc.
$77
GlaxoSmithKline, LLC.
$70
ABBVIE INC.
$69
Takeda Pharmaceuticals U.S.A., Inc.
$65
JAZZ PHARMACEUTICALS INC.
$64
SpringWorks Therapeutics, Inc.
$41
BeiGene USA, Inc.
$37
Myriad Genetic Laboratories, Inc.
$35
GENZYME CORPORATION
$32
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
ImmunoGen, Inc.
$29
Janssen Biotech, Inc.
$23
Blueprint Medicines Corporation
$23
Boston Scientific Corporation
$20
Azurity Pharmaceuticals, Inc.
$17
Top 3 companies account for 26.1% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,364
PFIZER INC.
$602
Merck Sharp & Dohme LLC
$576
Regeneron Healthcare Solutions, Inc.
$471
Exelixis Inc.
$362
Secura Bio, Inc.
$358
Celgene Corporation
$337
Novartis Pharmaceuticals Corporation
$317
Gilead Sciences, Inc.
$295
Bayer Healthcare Pharmaceuticals Inc.
$264
AstraZeneca Pharmaceuticals LP
$260
Adaptive Biotechnologies Corporation
$244
Amgen Inc.
$239
Takeda Pharmaceuticals U.S.A., Inc.
$211
Genentech USA, Inc.
$203
Incyte Corporation
$188
Eisai Inc.
$175
PharmaEssentia USA Corporation
$144
EMD Serono, Inc.
$132
Mirati Therapeutics, Inc.
$112
ARRAY BIOPHARMA INC
$110
Daiichi Sankyo Inc.
$106
Janssen Biotech, Inc.
$105
GlaxoSmithKline, LLC.
$89
ABBVIE INC.
$69
ImmunoGen, Inc.
$68
JAZZ PHARMACEUTICALS INC.
$64
Boehringer Ingelheim Pharmaceuticals, Inc.
$57
Seattle Genetics, Inc.
$54
BeiGene USA, Inc.
$50
SpringWorks Therapeutics, Inc.
$41
Myriad Genetic Laboratories, Inc.
$35
Boston Scientific Corporation
$35
GENZYME CORPORATION
$32
Deciphera Pharmaceuticals Inc.
$30
Lilly USA, LLC
$30
Alnylam Pharmaceuticals Inc.
$28
Teva Pharmaceuticals USA, Inc.
$25
Puma Biotechnology, Inc.
$25
Pharmacyclics LLC, An AbbVie Company
$24
Blueprint Medicines Corporation
$23
Bayer HealthCare Pharmaceuticals Inc.
$22
Clovis Oncology, Inc.
$19
Astellas Pharma US Inc
$18
Azurity Pharmaceuticals, Inc.
$17
INSYS Therapeutics Inc
$13
Top 3 companies account for 31.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AUGTYRO · AYVAKIT · Alecensa · Avastin · BAVENCIO · BENDEKA · BESREMI · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CALQUENCE · CARVYKTI · COPIKTRA · CYRAMZA · Cabometyx · ELAHERE · ENHERTU · ERBITUX · ERLEADA · Elahere · Enhertu · FASLODEX · Fabhalta · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUX-Dx Insertable Cardiac Monitor · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYRISK · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OPDIVO · OPDUALAG · PADCEV · PEMAZYRE · PLUVICTO · PROMACTA · Pomalyst · QINLOCK · REBLOZYL · RYDAPT · Revlimid · Rubraca · SARCLISA · SPRYCEL · SUTENT · SYNDROS · Stivarga · TAGRISSO · TECENTRIQ · TRELEGY ELLIPTA · VENCLEXTA · VIVIMUSTA · Venclexta · WaveWriter Alpha Prime 16 · XTANDI · ZEPZELCA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
404
Per 100K population
4.1
County median income
$87,760
Nearest hospital
DOCS SURGICAL HOSPITAL
2.3 mi
2.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hahn is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hahn experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Hahn performed 1,054 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hahn receive payments from pharmaceutical companies?
Yes. Dr. Hahn received a total of $8,039 from 46 companies across 321 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hahn's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Hahn's average Medicare payment per service is $45. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hahn) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology